08/01/25 RELEASE REVIEW
Inventions Review: Reinaldo Faget-Mora Inventor Speaks
Fogonazo by Respiraclean
“The power against respiratory infections.”
Fogonazo is a rapid-action medical disinfection system designed to eliminate airborne pathogens responsible for pneumonia, acute respiratory infections, and hospital-acquired respiratory diseases, especially in high-risk clinical environments.
RespiraClean – Patented Inhalation Treatment for Respiratory Tract Disinfection
Innovative medical technology with a US-approved patent designed to prevent and support the treatment of respiratory infections through a non-invasive, safe, and effective method.
Interested in collaborating or learning more?
For collaborating - click on the blog menu at the top
If you would like us to send you more information - click on our support menu at the top
About the Treatment
RespiraClean® is an advanced treatment that uses inhalation of disinfectant agents derived from dichlorine monoxide (Cl₂O). This precursor gas reacts upon inhalation with liquid water molecules present in the respiratory mucosa and with water droplets in the inhaled air, releasing hypochlorous acid (HClO), a powerful natural antimicrobial agent.
This acid acts directly on the respiratory tract to eliminate viruses, bacteria, and fungi without damaging epithelial cells, leveraging a natural mechanism of the innate immune system.
Treatment Advantages:
Non-invasive and safe application
The active molecule (hypochlorous acid) reaches all parts of the respiratory tract, from the nose to the lungs
High efficacy against a wide range of pathogens
High concentrations of hypochlorous acid with very low amounts of dichlorine monoxide, ensuring safety and effectiveness
Can be used as a preventive method in high-risk environments
Suitable for hospital and home use
Ideal for prevention and therapeutic support
Low operational cost
Effective even if microorganisms mutate, ensuring continuous antimicrobial action
Technology and Safety
RespiraClean® uses dichlorine monoxide (Cl₂O) which, upon inhalation, reacts with liquid water molecules in the mucosa and small water droplets in the air, releasing hypochlorous acid (HClO). This natural antimicrobial compound deactivates viruses, bacteria, and fungi on the mucosal surface without damaging respiratory cells.
The formulation ensures controlled and safe release of hypochlorous acid, complying with clinical standards described in patent US 11,957,711.
Patent Information
US Patent Number: US 11,957,711
Holder: Reinaldo Faget-Mora
Status: Patent granted by USPTO
Availability: Seeking collaboration for clinical development, investment, and licensing
Collaboration
We seek strategic partners to advance clinical validation, technological development, and commercialization:
Medical and research institutions
Pharmaceutical and biotech laboratories
Health innovation investors and funds
Regulatory advisors (FDA, EMA)
Access to Technical Information
Detailed information is available under a confidentiality agreement (NDA). Request the NDA or contact us for more information:
inventkingdom@gmail.com
Click here to download:
